Hepatic Encephalopathy, Minimal Hepatic Encephalopathy
Conditions
Keywords
Minimal hepatic encephalopathy, Hepatic encephalopathy, Subclinical hepatic encephalopathy, Health related quality of life
Brief summary
Minimal hepatic encephalopathy (MHE) has a negative effect on patients' daily functioning. No study has so far investigated the effect of treatment related improvement in cognitive functions on health related quality-of-life (HRQOL). This study was carried out to determine the influence of treatment on psychomotor performance and on HRQOL in patients with MHE. The mean number of abnormal NP tests decreased significantly in patients in treated group compared with patients in untreated group MANOVA for time and treatment, P =.001). Mean total SIP score improved among patients in the treated group after 3 months compared with patients in untreated group after 3 months (MANOVA for time and treatment, P=.002). Improvement in HRQOL was related to the improvement in psychometry. In conclusion, treatment with lactulose improves both cognitive functions and HRQOL in cirrhotic patients with MHE.
Detailed description
The study has been published in March 2007 in Hepatology Lactulose Improves Cognitive Functions and Health-Related Quality of Life in Patients with Cirrhosis WhoHave Minimal Hepatic Encephalopathy.Srinivasa Prasad, Radha K. Dhiman, Ajay Duseja, Yogesh K. Chawla, Arpita Sharma, and Ritesh Agarwal. (HEPATOLOGY 2007;45:549-559.)
Interventions
DRUGLactulose
Sponsors
Post Graduate Institute of Medical Education and Research, Chandigarh
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* All the patients diagnosed as having cirrhosis of liver
Exclusion criteria
* Overt HE or a history of overt HE; * History of recent (\< 6 weeks) alcohol intake; * Infection, recent (\< 6 weeks) antibiotic use or gastrointestinal bleeding; * History of recent (\< 6 weeks) use of drugs affecting psychometric * Performances like benzodiazepens, antiepileptics, psychotropic drugs; * History of shunt surgery or transjugular intrahepatic portosystemic shunt for portal hypertension; * Electrolyte imbalance; * Renal impairment; * Presence of hepatocellular carcinoma; * Severe medical problems such as congestive heart failure, pulmonary disease, neurological or psychiatric disorder, etc., that could influence quality-of-life measurement; * Inability to perform NP tests and to complete the SIP questionnaire due to bad vision.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in minimal hepatic encephalopathy and health related quality of life | — |
Countries
India
Outcome results
None listed